^
+ Follow DR. JOSEPH TOVERA Tag
Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 833899
                    [Title] => Novartis cancer drug gets Phl FDA approval
                    [Summary] => 

The Novartis anti-cancer drug everolimus, in combination with aromatase inhibitor, is now approved in the Philippines for the treatment of hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced breast cancer, in postmenopausal women after recurrence or progression following endocrine therapy.

[DatePublished] => 2012-08-02 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [1] => Array ( [ArticleID] => 779855 [Title] => Novartis, NKTI tie up to help GEP NET patients [Summary] =>

Novartis Oncology has formed an alliance with the National Kidney and Transplant Institute (NKTI) to help improve the diagnosis and management of patients with gastroenteropancreatic neuroendocrine tumors (GEP NETs), a form of cancer frequently difficult to diagnose and treat or manage.

[DatePublished] => 2012-02-23 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [2] => Array ( [ArticleID] => 700713 [Title] => Novartis partners with TMC to enhance gastrointestinal stromal tumor mg't [Summary] =>

Research-based health care company Novartis has partnered with The Medical City (TMC) to enhance the diagnosis and treatment of gastrointestinal stromal tumor (GIST) in the country.

[DatePublished] => 2011-06-30 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) ) )
DR. JOSEPH TOVERA
Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 833899
                    [Title] => Novartis cancer drug gets Phl FDA approval
                    [Summary] => 

The Novartis anti-cancer drug everolimus, in combination with aromatase inhibitor, is now approved in the Philippines for the treatment of hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced breast cancer, in postmenopausal women after recurrence or progression following endocrine therapy.

[DatePublished] => 2012-08-02 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [1] => Array ( [ArticleID] => 779855 [Title] => Novartis, NKTI tie up to help GEP NET patients [Summary] =>

Novartis Oncology has formed an alliance with the National Kidney and Transplant Institute (NKTI) to help improve the diagnosis and management of patients with gastroenteropancreatic neuroendocrine tumors (GEP NETs), a form of cancer frequently difficult to diagnose and treat or manage.

[DatePublished] => 2012-02-23 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [2] => Array ( [ArticleID] => 700713 [Title] => Novartis partners with TMC to enhance gastrointestinal stromal tumor mg't [Summary] =>

Research-based health care company Novartis has partnered with The Medical City (TMC) to enhance the diagnosis and treatment of gastrointestinal stromal tumor (GIST) in the country.

[DatePublished] => 2011-06-30 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) ) )
abtest
Are you sure you want to log out?
X
Login

Philstar.com is one of the most vibrant, opinionated, discerning communities of readers on cyberspace. With your meaningful insights, help shape the stories that can shape the country. Sign up now!

Get Updated:

Signup for the News Round now

FORGOT PASSWORD?
SIGN IN
or sign in with